Newsfeed | Navigating EGFR

Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach

Read more about Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach

Abstract Despite the initial success of EGFR-targeted therapies in non-small cell lung cancer (NSCLC), the emergence of drug resistance remains a significant clinical challenge. While several approved anticancer drugs exist, the development of resistance to current EGFR inhibitors necessitates the...

Deep learning framework for predicting EGFR mutation status from H&E whole slide images in lung adenocarcinoma

Read more about Deep learning framework for predicting EGFR mutation status from H&E whole slide images in lung adenocarcinoma

AbstractBackground Epidermal growth factor receptor (EGFR) mutations are pivotal molecular drivers in lung adenocarcinoma (LUAD) with significant therapeutic implications, yet conventional molecular testing remains costly, time-consuming, and limited by tissue availability. This study aimed to develop and validate a pathology-based...

TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling

Read more about TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling

AbstractBackground Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating malignancies worldwide, characterized by late diagnosis, rapid progression, and dismal survival rates. The discovery of reliable biomarkers for early detection and disease monitoring remains an urgent clinical need. Owing to...

A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC

Read more about A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC

Background/ObjectivesNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth Abstract Background/Objectives: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally. Resistance to third-generation epidermal growth factor receptor...

Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement

Read more about Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement

Open AccessArticle Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement by Ryo EnokiRyo Enoki SciProfiles Scilit Preprints.org Google Scholar 1,*, Mariko MiyazakiMariko Miyazaki SciProfiles Scilit Preprints.org Google Scholar 1, Enyu ImaiEnyu Imai SciProfiles Scilit Preprints.org...

SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma

Read more about SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and often fatal cancer with limited treatment options. Small nucleolar RNA host gene 10 (SNHG10) has emerged as a key regulator in the progression and metastasis of human cancers. However, the potential of...

Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation

Read more about Identification of a personalized eGFR threshold improves the prediction of kidney failure risk after transplantation

Background Many factors cause kidney transplant graft failure. To identify at-risk patients and tailor treatment, failure risks must be accurately predicted. We are trying to predict the temporal progression of graft function (as treated with estimated glomerular filtration rate) using...

[177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study

Read more about [177Lu]Lu-DOTA-IBA plus EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) with bone metastases: a prospective study

AbstractPurpose To evaluate the efficacy and safety of [177Lu]Lu-DOTA-IBA combined with maintenance EGFR-TKIs versus [177Lu]Lu-DOTA-IBA monotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) and bone metastases. Methods In this prospective, single-center study, 52 patients with EGFR-mutated NSCLC and...

Discovery of novel 1,2,3-Triazole hybrids containing quinoline-imidazole moieties as EGFR/HER2 dual inhibitors

Read more about Discovery of novel 1,2,3-Triazole hybrids containing quinoline-imidazole moieties as EGFR/HER2 dual inhibitors

Abstract EGFR and HER2 are overexpressed in numerous malignancies, including breast cancer. A novel series of 1,2,3-triazole hybrids comprising quinoline-imidazole moieties was created as part of an ongoing endeavor to find new anticancer drugs targeting these proteins. Several analytical techniques,...

Subscribe to Newsfeed